Canadian provider perspectives on Collagenase Clostridium histolyticum for the treatment of Peyronie's disease and the impact of its discontinuation.
Journal
International journal of impotence research
ISSN: 1476-5489
Titre abrégé: Int J Impot Res
Pays: England
ID NLM: 9007383
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
14
02
2021
accepted:
05
07
2021
revised:
03
07
2021
pubmed:
17
7
2021
medline:
23
9
2022
entrez:
16
7
2021
Statut:
ppublish
Résumé
Intralesional Collagenase Clostridium histolyticum (CCh) was the first non-surgical therapy approved for Peyronie's disease (PD). However, CCh's cost and poor market uptake has led to its discontinuation in Europe and Canada. In Canada, Xiaflex® is the trade name for CCh and it is produced by Paladin Labs Inc, an operating company of Endo International. The paper aims to better understand Canadian CCh providers' perspectives regarding its treatment efficacy and the potential impact of its discontinuation. All Xiaflex®-approved Canadian providers were asked to complete an anonymous 21-question survey using an online platform. Analysis consisted of descriptive statistics. Outcomes of interest included previous experience with CCh, protocols utilized, experience with insurance coverage, clinical and patient-reported outcomes, and provider perspectives on the discontinuation of CCh. Overall response rate was 48.3% (29/60). A total of 89% of respondents were male, 61% were in practice more than 10 years, 32% were in an academic practice, and 46% had completed an Andrology/Sexual Medicine fellowship. A total of 93% of respondents felt that CCh was superior to other intralesional therapies for PD. In all, 86% reported a patient satisfaction rate of at least 50%, and the majority (75%) saw a clinically meaningful response. Only 7% expressed difficulty obtaining insurance coverage, with many providers (71%) achieving an insurance approval rate between 75 and 100%. Only 54% of respondents reported that they would continue treating PD in light of CCh's discontinuation, and 96% felt that CCh's discontinuation represents a loss to Canadian patients. In light of CCh's discontinuation, most (79%) are now more likely to offer surgical treatment. In conclusion, most CCh providers found CCh to be effective and were dismayed by its discontinuation. The survey demonstrated that due to the withdrawal of CCh from Canada, physicians' abilities to offer effective medical therapy may become limited, with more providers offering surgical options for PD.
Identifiants
pubmed: 34267363
doi: 10.1038/s41443-021-00458-z
pii: 10.1038/s41443-021-00458-z
doi:
Substances chimiques
Microbial Collagenase
EC 3.4.24.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
599-602Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175:2115–28.
doi: 10.1016/S0022-5347(06)00270-9
Taylor FL, Levine LA. Peyronie’s disease. Urologic Clin NA. 2007;34:517–34.
doi: 10.1016/j.ucl.2007.08.017
Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991;146:1007–9.
doi: 10.1016/S0022-5347(17)37988-0
Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171:2350–3.
doi: 10.1097/01.ju.0000127744.18878.f1
Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, et al. Epidemiology of Peyronie’s disease. Int J Impot Res. 2002;14:379–83.
doi: 10.1038/sj.ijir.3900863
DiBenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503.
Smith JF, Walsh TJ, Conti SL, Turek P, Lue T. Risk factors for emotional and relationship problems in Peyronie’s disease. J Sex Med. 2008;5:2179–84.
doi: 10.1111/j.1743-6109.2008.00949.x
Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W, et al. Impact of Peyronie’s disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008;5:1977–84.
doi: 10.1111/j.1743-6109.2008.00883.x
Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie’s disease. J Sex Med. 2008;5:1985–90.
doi: 10.1111/j.1743-6109.2008.00895.x
Bella AJ, Lee JC, Grober ED, Carrier S, Benard F, Brock GB. 2018 Canadian Urological Association guideline for Peyronie’s disease and congenital penile curvature. CUAJ. 2018;12:E197–209.
doi: 10.5489/cuaj.5255
Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of Collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.
doi: 10.1016/j.juro.2013.01.087
Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194:745–53.
doi: 10.1016/j.juro.2015.05.098
Cordon BH, Hofer MD, Hutchinson RC, Broderick GA, Lotan Y, Morey AF. Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie’s disease deformities. Urol Pract. 2017;4:118–25.
doi: 10.1016/j.urpr.2016.04.005
Harvey N, Pearce I. At what cost is collagenase clostridium histolyticum viable for treating Peyronie’s disease in a public healthcare system? Andrology. 2020;8:1304–11.
doi: 10.1111/andr.12830
Abdel-Raheem A, Johnson M, Abdel-Raheem T, Capece M, Ralph D. Collagenase Clostridium histolyticum in the treatment of Peyronie’s disease—a review of the literature and a new modified protocol. Sex Med Rev. 2017;5:529–35.
doi: 10.1016/j.sxmr.2017.07.005
Capece M, Arcaniolo D, Manfredi C, Palmieri A, De Sio M, Verze P, et al. Second cycle of intralesional Collagenase Clostridium histolyticum for Peyronie’s disease using the modified shortened protocol: Results from a retrospective analysis. Andrologia. 2020;52:e13527.
doi: 10.1111/and.13527
Cocci A, Russo GI, Salamanca JIM, Ralph D, Palmieri A, Mondaini N. The end of an era: withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European market. Eur Urol. 2020;77:660–1.
doi: 10.1016/j.eururo.2019.11.019
Paladin Labs Inc. Healthcare professional information regarding discontinuation of XIAFLEX®. April 30, 2020. https://dupuytrencanada.ca/wp-content/uploads/2020/05/60841-002-Xiaflex_Discontinuation_Notice_04302020.pdf
Hellstrom WJG, Tue Nguyen HM, Alzweri L, Chung A, Virasoro R, Tapscott A, et al. Intralesional Collagenase Clostridium histolyticum causes meaningful improvement in men with Peyronie’s disease: results of a multi-institutional analysis. J Urol. 2019;201:777–82.
doi: 10.1097/JU.0000000000000032